

## Low *Zip 4* gene expression levels in RPMI - 8226 and ARH - 77 cell lines support the possible role of *zip 4* transporter protein in plasma cell tumorigenesis

*RPMI-8226 ve ARH-77 hücre hatlarında düşük Zip 4 gen ekspresyon düzeyi bulgusu plazma hücrelerinden köken alan tümörlerin gelişiminde Zip 4 taşıyıcı proteininin olası rolünü desteklemektedir*

Zehra Dilşad Çoban, Deniz Torun, Ferit Avcu, Ali Uğur Ural, Erhan Pariltay, Salih Kozan, Şefik Güran\*

Department of Medical Biology (Z. D. Çoban, MD, Prof. Ş. Güran, MD), Department of Genetics (D. Torun, MD, E. Pariltay, MD, S. Kozan, MD), Department of Hematology (Assoc. Prof. F. Avcu, Prof. A. U. Ural, MD), Gülhane Military Medical Academy, TR-06010 Ankara

### Abstract

**Aim.** Multiple myeloma and plasma cell leukemia are cancers of plasma cells. Multiple myeloma rarely transforms to plasma cell leukemia during the progression period. Zinc as a chemical element modulates proliferation and differentiation of cells by affecting several growth factors. *Zip 4* modifies zinc metabolism in a cell as a transporter protein. While high *Zip 4* gene expression was found in pancreas and hepatocellular carcinoma, low *Zip 4* gene expression was observed in prostate carcinoma. **Methods.** Here, *Zip 4* expression levels were studied in RPMI - 8226 and ARH - 77 cell lines as examples of multiple myeloma and plasma cell leukemia, respectively. **Results.** We found lower *Zip 4* gene expression levels in both cell lines than that of the normal control (0,000157 in RPMI - 8226, 0,000227 in ARH - 77 cell lines and 1 in normal control) The findings were statistically significant ( $P < 0.05$ ). The expression levels of *Zip 4* gene in both cell lines were approximately similar. No statistical significance was found between the expression levels of *Zip 4* in both cell lines ( $P = 0.547$ ). **Conclusion.** The results of this study support the possible role of *Zip 4* gene expression in plasma cell dyscrasias. The similar result of *Zip 4* gene expression level in both cell lines may show that *Zip 4* has no role in the transformation of multiple myeloma to plasma cell leukemia.

**Keywords:** *Zip 4* gene, gene expression, multiple myeloma, plasma cell leukemia

### Özet

**Amaç.** Multipl myelom ve plazma hücreli lösemi, plazma hücresinden köken alan kanserlerdir. Hastalığın ileri evresinde multipl myelom nadiren plazma hücreli lösemi formuna döner. Kimyasal bir element olarak çinko farklı büyüme faktörleri üzerinden memeli hücrelerinde çoğalma ve farklılaşmayı düzenler. Taşıyıcı bir protein olarak *Zip 4* ise hücrede çinko metabolizmasında aktif rol alır. Pankreas ve karaciğer kanserlerinde artmış *Zip 4* gen ekspresyonu bulunurken, prostat kanserinde düşük *Zip 4* gen ekspresyonu tanımlanmaktadır. **Yöntemler.** Bu çalışmada, sırası ile multipl myelom ve plazma hücreli lösemilere örnek olabilecek RPMI - 8226 ve ARH - 77 hücre hatlarında *Zip 4* gen ekspresyon düzeyleri bakılmıştır. **Bulgular.** Her iki hücre hattında *Zip 4* gen ekspresyon düzeyi normale göre daha düşüktür (RPMI - 8226 hücre hattında 0,000157 ve ARH - 77 hücre hattında 0,000227). Elde edilen veriler istatistiksel olarak anlamlıdır ( $P < 0,05$ ). Her iki hücre hattında *Zip 4* gen ekspresyon düzeyleri birbirine çok yakın olarak bulunmuştur. Aralarında istatistiksel olarak anlamlı bir fark da bulunmamıştır ( $P = 0,547$ ). **Sonuç.** Sonuçlar plazma hücre diskrazilerinde *Zip 4* gen ekspresyonunun olası rolünü destekler niteliktedir. Her iki hücre hattında birbirine yakın bulunan *Zip 4* gen ekspresyon düzeyi *Zip 4*'ün multipl myelomanın plazma hücreli lösemiye dönüşmesinde rolü olmadığını ortaya koymaktadır.

**Anahtar sözcükler:** *Zip 4* geni, gen ekspresyonu, multipl myelom, plazma hücreli lösemi

**Geliş tarihi/Received:** August 24, 2012; **Kabul tarihi/Accepted:** January 21, 2013

**\*Corresponding author:**

Dr. Şefik Güran, Tıbbi Biyoloji Anabilim Dalı, Gülhane Askeri Tıp Akademisi, TR-06010 Ankara. E-mail: sefguran@yahoo.com

**Introduction**

Multiple myeloma (MM) and plasma cell leukemia (PCL) are the cancers of plasma cells [1]. PCL may be primary (de novo), or secondary. Secondary PCL generally evolves from MM. PCL in secondary cases may be accepted as a terminal phase of MM. Two cell lines, RPMI - 8226 and ARH - 77 are the examples of MM and PCL respectively [2, 3]. As known, zinc (Zn) is essential for the structures and functions of proteins and enzymes in mammalian cells [4]. It modulates the proliferation and differentiation of the cells by affecting several growth factors in signaling cascades [5]. Recently, Zn transporters have been found to play roles in carcinogenesis. *Zip 4* transporter protein as a member of Zrt - Irt - like protein (*Zip*) super family modifies zinc metabolism in the mammalian cells [6]. High *Zip 4* gene expression levels were reported in pancreas and hepatocellular cancers [7, 8]. Low *Zip 4* gene expression level was found in prostate cancer cell lines [9].

We studied the expression levels of *Zip 4* gene on RPMI - 8226 (originated from MM) and ARH - 77 (originated from PCL) cell lines. Mononuclear cells (MNCs) obtained from peripheral blood were used as normal control.

**Materials and methods**

**Cell culture and RNA isolation:** In this study, MM-RPMI - 8226 and PCL-ARH - 77 cell lines were used. MNCs were used as normal control. RPMI - 8226 (ATCC No: CCL - 155) and ARH - 77 (ATCC No: CRL - 1621) cell lines were obtained from American Tissue and Cell Culture (ATCC, LGC Standards GmbH Mercatorstr. 5146485 Wesel Germany.) MNCs were isolated from peripheral blood by using Ficoll gradient [10]. The cell lines were cultured in a standard protocol [11]. In the isolation of total RNAs from the cell lines and MNCs, a RNA isolation kit was used with the manufacturer's protocol (NucleoSpin RNA II, Macherey - Nagel). The integrity of RNA was verified following electrophoresis in 1% agarose gel with ethidium bromide staining.

**Real-time PCR analyses:** c DNA samples were obtained from total RNA's by using c DNA synthesis kit (RevertAid cDNA Synthesis Kit, Fermentas). For the gene expression profiles, real-time PCR (RT - PCR) analyses (Roche Applied Science: LightCycler® 480 System) was performed. SYBR Green (Appliedbiosystems) was used for detection. A standard protocol was used as previously described in RT - PCR analyses [7]. In our experiments, the following gene-specific primers were used: *Zip 4* m RNA [sense 5' AAGCACTGCTGCTGAACCTGGCCT 3'; antisense 5' GATGTCATCCTCGTACAGGGACAGCAGC 3']. GAPDH m RNA [sense 5' ACATCATCCCTGCCTCTACTGG 3'; antisense 5' TCCGACGCCTGCTTCACC 3'] [7].

Each sample analyzed in triplicate. RT - PCR efficiency in each condition was visualized by serial dilution of c DNA template. The melting-curve data were collected in each RT - PCR analyses to confirm PCR specificity. GAPDH primers were used for sample variation in internal control. The amount of RT - PCR product was measured by threshold cycle (Ct) value. The levels of *Zip 4* m RNAs were normalized with the levels of GAPDH mRNAs. In normalization procedure, the following equation was used: fold-change =  $2^{(Ct_{Gene} - Ct_{GAPDH})}$  [7, 12].

**Statistical analyses:** Three groups of *Zip 4* gene m RNA expression results (from two cell lines and control cells) were statistically analyzed by using "analysis of variance - ANOVA test". For a comparison procedure, Tukey-Kramer method was used to find out the significantly different group in our series.

## Results

In RT-PCR analyses, the relative expression values of *Zip 4* mRNA levels of both cell lines in accordance with MNCs were obtained (Figure 1). The relative value of *Zip 4* mRNA expressions were 0,000157 in RPMI - 8226 and 0,000227 in ARH - 77 cell lines (Figure 2). Low levels of *Zip 4* mRNAs were found in two cell lines in comparison with normal control (Figure 1). The inhibition of *Zip 4* mRNA expression in both cell lines was statistically significant ( $P < 0.05$ ). These results may represent the down regulation of *Zip 4* gene expression in MM and PCL.

As seen in figure 2, the expression levels of *Zip 4* gene in both cell lines were approximately similar. By using the same methodology, a comparison of the *Zip 4* mRNA levels between RPMI - 8226 and in ARH - 77 cell lines was done. According to these results, no statistical significance was observed among the *Zip 4* mRNA levels in two cell lines ( $P = 0.547$ ) (Table 1).

**Table 1. ANOVA statistical results in three groups (normal control MNCs and two cell lines) with correction by Tukey-Kramer method.**

	Significance (p value)	Results
RPMI-8226	0,000	Different
ARH-77	0,000	Different
MNC (Normal control)	0,000	Different
ARH-77	0,547	Similar
MNC (Normal control)	0,000	Different
RPMI-8226	0,547	Similar


## Discussion

RPMI - 8226 is a cell line obtained from MM tumor cells. ARH - 77 is a cell line obtained from PCL tumor cells. As known, these two cancers are originated from plasma cells. In clinical presentation, PCL is more aggressive than MM. The clinical features of PCL generally represent the common findings of acute leukemia and MM together [1-3].


Enhanced expression of the *Zip 4* gene is found in many different cancers including pancreas and hepatocellular cancers [7, 8]. *Zip 4* transporter protein can repress apoptosis and enhance cell-cycle and cell migration by using different pathways. The regulatory roles of *Zip 4* transporter proteins have been reported in especially Wnt/ $\beta$ -catenin, Notch, PI3/Kinase-AKT/mTOR and Hedgehog signaling pathways. So, it can effect on cancer growth and metastasis in a mammalian cell. Over expression of *Zip 4* gene is associated with significantly increased expression of Neuropilin - 1 protein (NRP-1), vascular endothelial growth factor (VEGF) and type IV collagenases like matrix metalloproteinase - 2 (MMP - 2) and matrix metalloproteinase 9 (MMP - 9) in pancreatic cancers. So, overexpression of *Zip 4* in pancreatic cancers with these factors support that *Zip 4* has an important role in tumor development of pancreatic cells [13-15].

Recently, lower expression levels of *Zip 4* gene were found in prostate carcinoma by Chen et al. [9]. Prostate carcinoma is the sole example to be associated with low *Zip 4* mRNA expression levels among different types of cancers in the literature. Significantly lower *Zip 4* mRNA expression levels were observed in our series like in prostate carcinoma (Figure 1 and 2). The inhibition of *Zip 4* mRNA levels in both cancer cell lines originated from plasma cells supports the possible role of *Zip 4* protein in tumor progression from plasma cells. There may be an unknown mechanism which affects the *Zip 4* mRNA expression in plasma cell tumors. *Zip 4* protein may have a tumor suppressor effect on plasma cells hence we found lower expression levels in plasma cell dyscrasias.

In practice, PCL can be accepted as an aggressive form of MM [3, 17]. So, the levels of *Zip 4* gene mRNA expression in these two cell lines may represent the possible role of *Zip 4* protein in the transformation of MM to PCL. Also, such a kind of finding may be used as a prognostic marker in MM cases [9, 16, 17]. The expression levels of *Zip 4* gene in MM and PCL originated cell lines were approximately similar in our series (Figure 2). According to our results, we may accept that *Zip 4* protein has no role in the transformation of MM to PCL.



**Figure 1.** The relative *Zip 4* mRNA levels of two cell lines in accordance with MNCs, (a) MNCs as control, (b) RPMI - 8226 cell line, (c) ARH - 77 cell line.



**Figure 2.** The relative *Zip 4* mRNA levels of two cell lines (a) RPMI - 8226 cell line, (b) ARH - 77 cell line.

## References

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. *Lancet* 2009; 374: 324-39.
2. Lorschach RB, Hsi ED, Dogan A, Fend F. Plasma cell myeloma and related neoplasms. *Am J Clin Pathol* 2011; 136: 168-82.
3. Albarracin F, Fonseca R. Plasma cell leukemia. *Blood Rev* 2011; 25: 107-12.
4. Berg JM, Shi Y. The galvanization of biology: A growing appreciation for the roles of zinc. *Science* 1996; 271: 1081-5.
5. Haase H, Rink L. Functional Significance of Zinc-Related Signaling Pathways in Immune Cells. *Annu Rev Nutr* 2009; 29: 133-52.

6. Kambe T, Weaver BP, Andrews GK. The genetics of essential metal homeostasis during development. *Genesis* 2008; 46: 214-28.
7. Weaver BP, Zhang Y, Hiscox S, Guo GL, Apte U, Taylor KM, Sheline CT, Wang L, Andrews GK. Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration. *PLoS One* 2010; 5.
8. Zhang Y, Bharadwaj U, Logsdon CD, Chen C, Yao Q, Li M. ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. *Clin Cancer Res* 2010; 16: 1423-30.
9. Chen QG, Zhang Z, Yang Q, Shan GY, Yu XY, Kong CZ. The role of zinc transporter ZIP4 in prostate carcinoma. *Urol Oncol* 2012; 30: 906-11.
10. Noble PB, Cutts JH. Separation of blood leukocytes by Ficoll gradient. *Can Vet J* 1967; 8: 110-1.
11. Coban ZD, Avcu F, Ural AU, Akyol M, Güran Ş. Cytotoxic effect of docetaxel on multiple myeloma cell lines (RPMI-8226) as a chemotherapeutic agent. *Gulhane Med J* 2011; 53: 258-63.
12. Jou MY, Hall AG, Philipps AF, Kelleher SL, Lönnerdal B. Tissue-specific alterations in zinc transporter expression in intestine and liver reflect a threshold for homeostatic compensation during dietary zinc deficiency in weanling rats. *J Nutr* 2009; 139: 835-41.
13. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; 321: 1801-6.
14. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, Bucana CD, Evans DB, Ellis LM. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. *Cancer* 2003; 98: 720-9.
15. Donahue T, Hines OJ. The ZIP4 pathway in pancreatic cancer. *Cancer Biol Ther* 2010; 9: 243-5.
16. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. *Br J Haematol* 2010; 150: 418-27.
17. Bladé J, Rosiñol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. *Leukemia* 2008; 22: 1651-7.